Results 261 to 270 of about 43,902 (289)

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

Journal of Bone and Mineral Research, 2018
Serge Ferrari, Richard Eastell, Michael McClung   +2 more
exaly   +2 more sources

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

New England Journal of Medicine, 2009
Steven Cummings, Michael McClung, Richard Eastell   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis.

Special Care in Dentistry: managing special patients, settings, and situations, 2023
OBJECTIVES This study aimed to assess the overall incidence of osteonecrosis of the jaw (ONJ) caused by bisphosphonates and denosumab when used for controlling bone cancer metastasis or as adjuvant therapy.
Chengrong Zhang, Guoshuang Shen, Huihui Li, Y. Xin, Mingqiang Shi, Yonghui Zheng, Miaozhou Wang, Zhen Liu, Yi Zhao, Fuxing Zhao, Dengfeng Ren, Jiuda Zhao   +11 more
semanticscholar   +1 more source

Comparable Efficacy of Denosumab and Romosozumab in Patients with Rheumatoid Arthritis Receiving Glucocorticoid Administration.

Modern Rheumatology, 2022
OBJECTIVES Romosozumab is a newly released and widely known molecular-targeted drug for severe osteoporosis treatment with comparable effectiveness to denosumab.
T. Kobayakawa, A. Miyazaki, Y. Kanayama, Y. Hirano, Jun Takahashi, Takako Suzuki, Yukio Nakamura   +6 more
semanticscholar   +1 more source

Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer.

NEJM Evidence, 2022
Outcomes of Adjuvant Denosumab in Breast CancerIn this long-term report of a prospective, double-blind, placebo-controlled, phase 3 trial of adjuvant aromatase inhibitor in postmenopausal patients with early hormone receptor-positive breast cancer ...
M. Gnant, S. Frantal, G. Pfeiler, G. Steger, D. Egle, R. Greil, F. Fitzal, V. Wette, M. Balić, F. Haslbauer, E. Melbinger-Zeinitzer, V. Bjelic-Radisic, S. Artner-Matuschek, F. Kainberger, M. Ritter, G. Rinnerthaler, P. Sevelda, J. Bergh, S. Kacerovsky-Strobl, C. Suppan, C. Brunner, C. Deutschmann, S. Gampenrieder, H. Fohler, R. Jakesz, C. Fesl, C. Singer   +26 more
semanticscholar   +1 more source

The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis

Calcified Tissue International, 2023
Magdalena Ruth Moshi, Konstance Nicolopoulos, Danielle Stringer, Ning Ma, Mathias Jenal, T. Vreugdenburg   +5 more
semanticscholar   +1 more source

Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis

Osteoporosis International, 2023
N. Hong, Sungjae Shin, Seunghyun Lee, Y. Rhee   +3 more
semanticscholar   +1 more source

The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial

Osteoporosis International, 2023
S. Ramchand, J. Tsai, Hang Lee, Grace Sassana-Khadka, Mackenzie Jordan, Savannah Ryan, B. Leder   +6 more
semanticscholar   +1 more source

Denosumab Discontinuation

Current Osteoporosis Reports, 2022
Anne Sophie Sølling, E. Tsourdi, T. Harsløf, B. Langdahl   +3 more
semanticscholar   +1 more source

Preoperative Denosumab Therapy Against Giant Cell Tumor of Bone is Associated with an Increased Risk of Local Recurrence After Curettage Surgery

Annals of Surgical Oncology, 2022
N. Asano, Masato Saito, E. Kobayashi, T. Morii, Kazutaka Kikuta, I. Watanabe, U. Anazawa, Katsuhito Takeuchi, Yoshihisa Suzuki, Michiro Susa, K. Nishimoto, Ryota Ishii, Naoki Miyazaki, Hideo Mrioka, A. Kawai, K. Horiuchi, R. Nakayama   +16 more
semanticscholar   +1 more source